sur Jaguar Health (NASDAQ:JAGX)
Jaguar Health Reports Second Quarter 2024 Financial Results
Jaguar Health, Inc. revealed a combined net revenue of approximately $2.72 million in Q2 2024. This represents a 16% increase from Q1 2024's $2.35 million and a 2% increase from Q2 2023's $2.67 million.
The company is set to begin the commercial launch of Gelclair® in October 2024 and will complete analysis of phase 3 trial data for crofelemer, aimed at prophylaxis of cancer therapy-related diarrhea (CTD). An import permit for crofelemer has been granted for a pediatric trial in Abu Dhabi for MVID and SBS with intestinal failure.
Financial highlights include a 1% rise in net revenue for Mytesi, decreasing losses from operations by $0.9 million, and a 13% reduction in operational costs. Jaguar's net loss attributable to common shareholders decreased from $12.1 million in Q2 2023 to $9.5 million in Q2 2024.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health